UGN-103 Shows Durable Disease Control in LG-IR-NMIBC, Paving Path for FDA SubmissionByJason M. BroderickMay 15th 2026
Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBCByJason M. BroderickMay 14th 2026